Edna Chow‐Maneval

4.0k total citations
24 papers, 724 citations indexed

About

Edna Chow‐Maneval is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Edna Chow‐Maneval has authored 24 papers receiving a total of 724 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 7 papers in Cancer Research. Recurrent topics in Edna Chow‐Maneval's work include Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Research Studies (5 papers) and Prostate Cancer Treatment and Research (5 papers). Edna Chow‐Maneval is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Research Studies (5 papers) and Prostate Cancer Treatment and Research (5 papers). Edna Chow‐Maneval collaborates with scholars based in United States, Australia and Japan. Edna Chow‐Maneval's co-authors include Pratik S. Multani, Stephen V. Liu, Anna F. Farago, Zachary Hornby, Alexander Drilon, Zongli Zheng, Leonard B. Saltz, A. John Iafrate, Herbert I. Hurwitz and Long P. Le and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Edna Chow‐Maneval

23 papers receiving 711 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Edna Chow‐Maneval United States 14 478 458 231 183 80 24 724
Fernando C. Santini United States 13 464 1.0× 685 1.5× 211 0.9× 143 0.8× 57 0.7× 34 958
G. Jeannin France 9 543 1.1× 465 1.0× 408 1.8× 165 0.9× 105 1.3× 21 840
Ursula Vogl Austria 9 417 0.9× 397 0.9× 341 1.5× 171 0.9× 71 0.9× 20 878
Erin Larkins United States 14 441 0.9× 637 1.4× 286 1.2× 162 0.9× 80 1.0× 28 937
Lyudmila Bazhenova United States 16 563 1.2× 534 1.2× 270 1.2× 114 0.6× 64 0.8× 83 749
Roman Groisberg United States 14 385 0.8× 442 1.0× 191 0.8× 167 0.9× 96 1.2× 50 742
Junpei Takashima Japan 4 718 1.5× 604 1.3× 483 2.1× 210 1.1× 104 1.3× 17 946
Tahsin M. Khan United States 8 364 0.8× 344 0.8× 275 1.2× 115 0.6× 61 0.8× 23 604
Anna Maria Calella Italy 5 658 1.4× 541 1.2× 195 0.8× 186 1.0× 64 0.8× 9 774

Countries citing papers authored by Edna Chow‐Maneval

Since Specialization
Citations

This map shows the geographic impact of Edna Chow‐Maneval's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edna Chow‐Maneval with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edna Chow‐Maneval more than expected).

Fields of papers citing papers by Edna Chow‐Maneval

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edna Chow‐Maneval. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edna Chow‐Maneval. The network helps show where Edna Chow‐Maneval may publish in the future.

Co-authorship network of co-authors of Edna Chow‐Maneval

This figure shows the co-authorship network connecting the top 25 collaborators of Edna Chow‐Maneval. A scholar is included among the top collaborators of Edna Chow‐Maneval based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edna Chow‐Maneval. Edna Chow‐Maneval is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Meneses‐Lorente, Georgina, Elena Guerini, François Mercier, et al.. (2023). Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations. Cancer Chemotherapy and Pharmacology. 91(3). 239–246. 2 indexed citations
2.
Meneses‐Lorente, Georgina, Darren Bentley, Elena Guerini, et al.. (2021). Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors. Investigational New Drugs. 39(3). 803–811. 26 indexed citations
3.
Meneses‐Lorente, Georgina, Stephen Fowler, Elena Guerini, et al.. (2021). In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK). Investigational New Drugs. 40(1). 68–80. 12 indexed citations
4.
5.
6.
Paz‐Ares, Luis, Robert C. Doebele, Anna F. Farago, et al.. (2019). Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001. Annals of Oncology. 30. ii48–ii49. 23 indexed citations
7.
Doebele, Robert C., Luis Paz‐Ares, Anna F. Farago, et al.. (2019). Abstract CT131: Entrectinib in NTRK-fusion positive (NTRK-FP) non-small cell lung cancer (NSCLC): Integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1 and ALKA-372-001). Cancer Research. 79(13_Supplement). CT131–CT131. 11 indexed citations
8.
Demetri, George D., Luis Paz‐Ares, Anna F. Farago, et al.. (2018). Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001. Annals of Oncology. 29. ix175–ix175. 30 indexed citations
9.
Demetri, George D., Luis Paz‐Ares, Anna F. Farago, et al.. (2018). Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Annals of Oncology. 29. viii713–viii713. 46 indexed citations
10.
Doebele, Robert C., Myung‐Ju Ahn, Salvatore Siena, et al.. (2018). OA02.01 Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 13(10). S321–S322. 36 indexed citations
11.
Pishvaian, Michael J., Ignacio Garrido‐Laguna, Stephen V. Liu, et al.. (2018). Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic Cancer. JCO Precision Oncology. 2(2). 1–7. 37 indexed citations
12.
Ambati, Srikanth, Emily K. Slotkin, Edna Chow‐Maneval, & Ellen M. Basu. (2018). Entrectinib in Two Pediatric Patients With Inflammatory Myofibroblastic Tumors Harboring ROS1 or ALK Gene Fusions. JCO Precision Oncology. 2(2). 1–6. 13 indexed citations
13.
Ahn, Myung‐Ju, Salvatore Siena, Alexander Drilon, et al.. (2017). OA 14.06 Entrectinib in Patients with Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 12(11). S1783–S1783. 13 indexed citations
14.
Farago, Anna F., Long P. Le, Zongli Zheng, et al.. (2015). Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 10(12). 1670–1674. 172 indexed citations
15.
16.
Smith, Matthew R., Emmanuel S. Antonarakis, Charles J. Ryan, et al.. (2014). Novel Antiandrogen Arn-509 in High-Risk Non-Metastatic (M0) Castration-Resistant Prostate Cancer (Crpc). Annals of Oncology. 25. iv258–iv258. 3 indexed citations
17.
Sonpavde, Guru, Gregory R. Pond, Andrew J. Armstrong, et al.. (2013). Radiographic progression by Prostate Cancer Working Group ( PCWG )‐2 criteria as an intermediate endpoint for drug development in metastatic castration‐resistant prostate cancer. British Journal of Urology. 114(6b). E25–E31. 35 indexed citations
18.
Smith, Mitchell R., Emmanuel S. Antonarakis, Charles J. Ryan, et al.. (2012). ARN-509 in Men with High Risk Non-Metastatic Castration-Resistant Prostate Cancer. Annals of Oncology. 23. ix303–ix303. 9 indexed citations
19.
Rathkopf, Dana E., Emmanuel S. Antonarakis, Neal D. Shore, et al.. (2012). ARN-509 in Men with Metastatic Castration-Resistant Prostate Cancer (CRPC). Annals of Oncology. 23. ix317–ix317. 5 indexed citations
20.
Saltz, Leonard B., Lee S. Rosen, John L. Marshall, et al.. (2007). Phase II Trial of Sunitinib in Patients With Metastatic Colorectal Cancer After Failure of Standard Therapy. Journal of Clinical Oncology. 25(30). 4793–4799. 128 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fernando C. Santini Breakdown of academic impact, for papers by G. Jeannin Breakdown of academic impact, for papers by Ursula Vogl Breakdown of academic impact, for papers by Erin Larkins Breakdown of academic impact, for papers by Lyudmila Bazhenova Breakdown of academic impact, for papers by Roman Groisberg Breakdown of academic impact, for papers by Junpei Takashima Breakdown of academic impact, for papers by Tahsin M. Khan Breakdown of academic impact, for papers by Anna Maria Calella
Rankless by CCL
2026